Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
170 hedge funds and large institutions have $1.51B invested in Acorda Therapeutics in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 65 increasing their positions, 61 reducing their positions, and 32 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 61
0% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $2.5M
1% less capital invested
Capital invested by funds: $1.53B → $1.51B (-$20.8M)
11% less funds holding
Funds holding: 190 → 170 (-20)
63% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 32
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$27.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.74M |
| 4 |
AC
Armistice Capital
New York
|
+$5.99M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$15.3M |
| 2 |
Millennium Management
New York
|
-$14M |
| 3 |
AG
Artal Group
Luxembourg
|
-$8.32M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$7.37M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$6.59M |
ACOR Hedge Fund Activity: Q2 2015 in Review
170 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2015, worth a combined $1.51B — down 1.4% from $1.53B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ACOR and 12 opened new positions — a net loss of 20 holders — while 61 trimmed existing stakes and 65 added.
The largest buyer was UBS AM, adding an estimated $27.2M. The largest seller was Morgan Stanley, cutting an estimated $15.3M.
- 170 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2015, down from 190 in Q1 2015.
- Funds reported $1.51B of Acorda Therapeutics stock for Q2 2015, down 1.4% quarter-over-quarter.
- 12 funds opened new Acorda Therapeutics positions in Q2 2015 and 32 closed out, a net change of -20 holders.
- The largest Acorda Therapeutics buyer in Q2 2015 was UBS AM, an estimated $27.2M added.
- The largest Acorda Therapeutics seller in Q2 2015 was Morgan Stanley, an estimated $15.3M sold.
Based on aggregated 13F filings for Q2 2015.